Boston Scientific (BSX)
Health Care · Medical Devices · NYSE
Boston Scientific is a leading medical device company dedicated to transforming lives through innovative, less-invasive medical solutions for a broad range of interventional specialties.
What Boston Scientific does
Boston Scientific is a global developer, manufacturer, and marketer of medical devices used in a wide range of interventional medical specialties. The company focuses on less-invasive technologies for interventional cardiology, peripheral interventions, electrophysiology, endoscopy, and urology. Their products are designed to treat various cardiovascular, digestive, pulmonary, and urological conditions.
Themes: interventional cardiology, electrophysiology, minimally invasive surgery, urology and pelvic health, neuromodulation, gastrointestinal endoscopy
Fundamentals
- Price$49.01 as of 2026-08-24 close
- Market cap$71.0B as of 2026-08-24
- 1-year return-53.8% 2025-08-22 close $106.17 → 2026-08-24 close $49.01
- P/E20.40 as of 2026-08-25
- Net margin+17.5% as of 2026-08-25
- Gross margin+69.5% as of 2026-08-25
- ROE+14.9% as of 2026-08-25
- Debt / equity0.51 as of 2026-08-25
- Revenue growth (YoY)+13.5% as of 2026-08-25
- Revenue CAGR (3y)+16.5% SEC XBRL
- Beta0.57 as of 2026-08-25
- Last reported earnings2026-07-29 SEC EDGAR Form 8-K (Item 2.02)
Dividend: does not currently pay a dividend.
How BSX compares in its sector
- price-to-earnings ratiomiddle range 203 covered Health Care peers, as of 2026-08-25
- net profit margintop 25% 504 covered Health Care peers, as of 2026-08-25
- operating margintop 25% 504 covered Health Care peers, as of 2026-08-25
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-25
- return on equitytop 25% 576 covered Health Care peers, as of 2026-08-25
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 10% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
BSX is not currently in any published Top 10 list. Its scores are below.
Long-term score
49.5 #853 of 1,605 scored · #100 of 195 in Health Care
Growth 72nd (3-year revenue CAGR 16.5%, revenue growth year over year 13.5%) and valuation 69th (price to earnings 19.9, price to book 2.8); weakest is long-term trend (8th, over the past 12 months this stock lagged the market by 72.1 percentage points).
Short-term score
42.6 #1099 of 1,698 scored · #179 of 236 in Health Care
Volume and participation 60th: it gapped 3.1% above the previous close and has not traded back through the level it left behind — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed; catalysts 59th: open-market insider buys in 90 days 21, the analyst consensus rating is unchanged since the prior reading; weakest is trend 0th: a "death cross" — its 50-day average is below its 200-day. Its trend score is set to zero: its 50-day average is below its 200-day and the price is below both.
Scores as of 24 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 3.
Dividend coverage
Not assessed — last reported dividend predates the accounts. The most recent fiscal year in which BSX reported a dividend payment is FY2023, while its reported financial statements run through FY2025. Coverage is therefore not assessed for the latest year — an FY2023 ratio would not describe BSX today.
Coverage is derived from reported SEC EDGAR XBRL figures, comparing dividends paid against net income and free cash flow for the SAME fiscal year. It is not shown here because the latest fiscal year with a reported dividend payment (FY2023) is older than the latest year of reported financial statements (FY2025), so any ratio would describe an out-of-date year. Informational only — not financial advice.
How Boston Scientific looks technically
Boston Scientific (BSX) is trading 29.9% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 211 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 16, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 51, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 1 trading day ago (its momentum flipped negative). It made a new 20-day high about 4 trading days ago. It is 55.2% below its highest point of the past year.
Trend
7
| Distance from the 200-day | it is trading 29.9% below its 200-day average, the long-term trend line — a long-term downtrend | -29.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $46.46 | $46.46 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $69.95 | $69.95 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 10 calendar days ago — the swings before that are what the structure reading is measured on | 10 sessions |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 211 trading days ago — a "death cross", a bearish long-term signal | 211 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 16, below the 25 that marks a real trend) | 15.9 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 51, neither overbought (above 70) nor oversold (below 30) | 50.7 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($47.10 to $52.99) — its "stochastic" reading is 32 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 32.4 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 1 trading day ago (its momentum flipped negative) | 1 session |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $109.50 | $109.50 |
|---|---|---|
| From the 52-week high | it is 55.2% below its 52-week high (its highest price of the past year) | -55.2% |
| Above the 52-week low | it is 16.1% above its 52-week low (its lowest price of the past year) | +16.1% |
| Below the 52-week high | it is 55.2% below its highest point of the past year | 55.2% |
| Since a 20-day breakout | it made a new 20-day high about 4 trading days ago | 4 sessions |
| Since a 55-day breakout | it made a new 55-day high about 4 trading days ago | 4 sessions |
| All-time high | its highest closing price on record is $109.50 (set on 2025-09-09) | $109.50 |
| Given back of the 52-week move | over the past year its closes ranged ($42.63 to $108.14), and it has recovered only a small part of its fall from last year’s high — 10% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $83.12 to $85.21. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 9.7% |
| From the all-time high | it is 55.2% below its all-time high | -55.2% |
| Nearest price level | it is trading 7.6% below a resistance level at $52.75 — a price it turned at twice since 2026-05-15, most recently on 2026-08-14. Since 2024-08-26 it has 1 such level below the current price and 14 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +7.6% |
| All-time low | its lowest closing price on record is $4.79 (set on 2012-07-26) | $4.79 |
| Above the all-time low | it is 923.2% above its all-time low | +923.2% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 40th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.73 between its high and its low — about 3.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.73 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $45.46 and $53.34 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $45.46 – $49.40 – $53.34 |
| Typical daily range (% of price) | its price moves about 3.5% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.5% |
| Stretch from the 200-day average | it is trading 12.1 daily ranges below its 200-day average price (29.9% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 12.1 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.83× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Price gaps
3
| Gap at the open | it opened on 2026-08-24 0.2% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.2% |
|---|---|---|
| Open gap | it gapped 3.1% above the previous close 12 sessions ago and has not traded back through the level it left behind at 47.74 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +3.1% |
| Gap filled | a 2.2% gap up opened on 2026-08-14 has been "filled" 5 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 5 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 7.4 percentage points (the stock gained 10.8% while the market gained 3.3%) | +7.4% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 17.6 percentage points (the stock lost 15.2% while the market gained 2.4%) | -17.6% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 45.9 percentage points (the stock lost 34.8% while the market gained 11.1%) | -45.9% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 72.1 percentage points (the stock lost 53.8% while the market gained 18.3%) | -72.2% |
Signal agreement
2
| Bullish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bullish state — these describe past price behaviour, not a forecast | 0 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, MACD momentum is negative, lagging the market over 6 months — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-17 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 10.5% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 18% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $60.12 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | -18.5% |
|---|---|---|
| Vs the average paid since it last reported | the price is sitting right on the average price paid since it last reported on 2026-07-29 (its 8-K), so the typical buyer over that stretch is roughly break-even. That average is $49.18 — a volume-weighted average of daily closes over 19 sessions, not a true tick-by-tick VWAP. | -0.3% |
Price levels it has turned at before
BSX last closed at $49.01 on 2026-08-24. Since 2024-08-26 it has turned at 1 price below its last close and 14 above; the nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $52.75 | Resistance | 7.6% above the last close | turned there twice · 2026-05-15 to 2026-08-14 |
| $42.32 | Support | 13.7% below the last close | turned there three times · 2026-06-30 to 2026-07-23 |
| $58.34 | Resistance | 19.1% above the last close | turned there twice · 2026-05-07 to 2026-05-22 |
| $67.22 | Resistance | 37.2% above the last close | turned there twice · 2026-03-12 to 2026-04-23 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-24.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · MACD just crossed bearish (12/26/9) · trendless / choppy (low ADX) · lagging the market · Stretched far below its 200-day average (6+ daily ranges) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-24. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.58 mean, 1=Strong Buy…5=Strong Sell) — 29 analysts
- Mean price target$62.69 range $44.00 – $94.00; median $60.00
Analyst estimates, as of 2026-08-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for BSX
- Consensus EPS estimate$0.8053 next reporting period, as of 2026-08-18
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Litigation-related legal risks and potential charges.","Dependence on the successful development and regulatory approval of new, less-invasive medical technologies.","Exposure to complex global regulatory, environmental, and healthcare reimbursement environments."]
What changed in the latest 10-Q
AI-assisted comparison of BSX's 10-Q filed 2026-05-01 against the prior one filed 2025-11-03.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-01) adds 'Executive Summary' section header after Introduction, whereas older filing (2025-11-03) transitions directly from Introduction to 'Financial Summary' section
- Removed:
- Older filing (2025-11-03) contains detailed 'Financial Summary' section with three months ended September 30, 2025 net sales data ($5.065 billion), net income, and reconciliation tables—this entire section is removed/not present in newer filing (2026-05-01)
- Older filing (2025-11-03) contains detailed 'Nine Months Ended September 30, 2025' financial data and narrative—this section is removed/not present in newer filing (2026-05-01)
- Reworded:
- Newer filing (2026-05-01) uses 'Executive Summary' as the section heading following Introduction, whereas older filing (2025-11-03) uses 'Financial Summary'
- Notes:
- Newer filing text appears truncated at end of provided excerpt ('dil' cut off mid-word), limiting full comparison of content below the Executive Summary introduction
- Comparison is limited to the excerpt provided; full MD&A sections may contain additional differences not visible in the truncated text
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
1 open-market purchase and 0 open-market sales by insiders in the last 90 days.
- Last 30 days1 buy ($227400) · 0 sells — 1 buying insider
- Last 90 days1 buy ($227400) · 0 sells — 1 buying insider
- Last 180 days5 buys ($781399) · 0 sells — 3 buying insiders
Cluster buying: 3 different insiders reported open-market purchases (SEC code P) of BSX within a 30-day window between 2026-05-19 and 2026-05-20. Disclosed Form 4 activity, not a prediction of performance or a buy signal.
Activity heuristic: net buying (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-31. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about BSX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 28 matched disclosures for BSX from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
6 institutional 13F filers reported holding BSX as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 284,003,890
- Reported value $17,821,244,139
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 3 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
BSX had 22,276,201 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
BSX had 1.54% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 1.01 days to cover at the same settlement.
- Reported short interest (shares) 22,276,201
- Short interest (% of shares outstanding) 1.54%
- Prior settlement (shares) 28,281,040
- Reported change -21.23%
- Days to cover (reported) 1.01
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Medtronic (MDT)
- Abbott Laboratories (ABT)
- Edwards Lifesciences (EW)
- Johnson & Johnson (JNJ)
- Stryker (SYK)
- Becton, Dickinson and Company (BDX)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare BSX vs…
Boston Scientific is found in…
BSX shows up in…
Frequently asked questions
What does Boston Scientific (BSX) do?
Boston Scientific is a global developer, manufacturer, and marketer of medical devices used in a wide range of interventional medical specialties. The company focuses on less-invasive technologies for interventional cardiology, peripheral interventions, electrophysiology, endoscopy, and urology. Their products are designed to treat various cardiovascular, digestive, pulmonary, and urological conditions.
What sector is Boston Scientific (BSX) in?
Boston Scientific (BSX) is classified in the Health Care sector. Its industry is Medical Devices. It trades on NYSE.
Does BSX pay a dividend?
No — Boston Scientific (BSX) does not currently pay a dividend (market data, as of 2026-08-25). Informational only — not financial advice.
Who are Boston Scientific's (BSX) competitors?
Notable peers of Boston Scientific (BSX) include Medtronic, Abbott Laboratories, Edwards Lifesciences, Johnson & Johnson and Stryker. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in BSX?
Yes — we hold 28 matched STOCK Act disclosures for BSX from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Boston Scientific (BSX) overbought or oversold right now?
Boston Scientific (BSX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 51, in the neutral middle (as of 2026-08-24). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on BSX come from?
Fundamentals and prices come from market data, as of 2026-08-25; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-25. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.